In conclusion, our findings substantiate that SRGN and its binding partners promote ESCC aggressiveness from multiple aspects, including autocrine activation of intracellular signaling pathway and tumor microenvironment remodeling. The gene discussed is SRGN; the disease is esophageal squamous cell carcinoma.